Premium
A Peptide Antagonist of the TLR4–MD2 Interaction
Author(s) -
Slivka Peter F.,
Shridhar Mitesh,
Lee Guiin,
Sammond Deanne W.,
Hutchinson Mark R.,
Martinko Alexander J.,
Buchanan Madison M.,
Sholar Page W.,
Kearney Jeffrey J.,
Harrison Jacqueline A.,
Watkins Linda R.,
Yin Hang
Publication year - 2009
Publication title -
chembiochem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.05
H-Index - 126
eISSN - 1439-7633
pISSN - 1439-4227
DOI - 10.1002/cbic.200800769
Subject(s) - tlr4 , receptor , endogeny , peptide , toll like receptor , central nervous system , innate immune system , neuroscience , antagonist , blocking (statistics) , immunology , biology , pharmacology , medicine , biochemistry , computer science , computer network
Toll‐like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll‐like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS‐related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4–MD2 association, thereby blocking TLR4 signaling.